Otsuka said its monoclonal antibody Voyxact (in IgA nephropathy) slowed kidney function decline in a one-year Phase 3 period, but the benefit was less than expected versus historical expectations and left room for competitors. In the Phase 3 data, patients treated with Voyxact saw annualized eGFR loss of 3.0 points compared with 7.6 points in the placebo arm. The company also framed overall safety and tolerability as manageable, while emphasizing regulatory intent. For biotech teams, the practical takeaway is that the efficacy signal is credible but not dominant, raising the bar for differentiation in endpoints, durability, and patient subgroups as sponsors prepare payor and regulatory narratives. The readout also keeps competitive scrutiny high in IgA nephropathy, where earlier lines of development and next-generation agents can shift uptake even with statistically significant kidney outcomes.